Blockade of C5aR1 prevented disease expression, and C5aR2 deficiency aggravated the disease condition; antagonism is being tested as a therapy for patients with ANCA-associated vasculitis [26,29]. This evidence concerns the gene C5AR2 and anti-neutrophil cytoplasmic antibody-associated vasculitis.